Abstract
In this review, we discuss the role of the endocannabinoid (eCB) system in regulating energy and metabolic homeostasis. Endocannabinoids, via activating the cannabinoid type-1 receptor (CB1R), are commonly known as mediators of the thrifty phenotype hypothesis due to their activity in the central nervous system, which in turn regulates food intake and underlies the development of metabolic syndrome. Indeed, these findings led to the clinical testing of globally acting CB1R blockers for obesity and various metabolic complications. However, their therapeutic potential was halted due to centrally mediated adverse effects. Recent observations that highlighted the key role of the peripheral eCB system in metabolic regulation led to the preclinical development of various novel compounds that block CB1R only in peripheral organs with very limited brain penetration and without causing behavioral side effects. These unique molecules, which effectively ameliorate obesity, type II diabetes, fatty liver, insulin resistance, and chronic kidney disease in several animal models, are likely to be further developed in the clinic and may revive the therapeutic potential of blocking CB1R once again.
Original language | English |
---|---|
Article number | 275 |
Journal | Toxins |
Volume | 11 |
Issue number | 5 |
DOIs | |
State | Published - May 2019 |
Bibliographical note
Funding Information:Funding: This review article was made possible by the financial support provided by the ERC-2015-StG grant (#676841) to J.T.
Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords
- CB1 receptor
- Cannabis
- Central CB1 receptor blockade
- Marijuana
- Peripheral CB1 receptor blockade